新加坡学者撰文：战略、规模和效率助力中国创新药物迅猛发展

Core Insights - The article discusses the competitive landscape of innovative pharmaceuticals, highlighting that while the U.S. leads in original innovation, China is rapidly advancing through strategy, scale, and efficiency, shaping the future of the global pharmaceutical industry [1][2] Group 1: U.S. and China's Competitive Landscape - The U.S. has maintained its dominance in innovative pharmaceuticals due to strong foundational research and a mature venture capital ecosystem [1] - China's biomanufacturing industry has developed rapidly over the past decade, driven by policy and capital, leading to a comprehensive competition between the U.S. and China that extends beyond market share to key technologies and global health strategies [1][2] Group 2: China's Strategic Approaches - China's biomanufacturing development is a result of national strategic vision, a large market, and regulatory reforms, with its population providing unique advantages for patient recruitment and clinical trials [2] - Differentiated competition is a key strategy for China, focusing on diseases common in Asia, such as liver cancer and dengue fever, allowing companies to leverage local knowledge into global advantages [2] - The competition in innovative pharmaceuticals reflects the broader U.S.-China tech rivalry, with the potential for healthy competition to accelerate drug development and reduce costs for patients globally [2] Group 3: Future Outlook - For Chinese biopharmaceutical companies, achieving differentiated breakthroughs in specific disease and technology areas is a more realistic path forward [2] - A global perspective in research strategies and high-quality international collaborations is essential for China to secure an indispensable position in the global landscape [2]